Beximco Pharmaceuticals Limited (Dhaka) (Bangladesh)

The Company is a leading manufacturer and exporter of medicines based in Bangladesh. Founded in 1976, the Company started its operations by importing and marketing pharmaceutical products from Bayer, Germany and Upjohn, USA.
By 1980, Beximco Pharma began manufacturing these products locally under licensing agreements but quickly transitioned to manufacturing its own proprietary formulations in 1983, marking a significant milestone in its journey.
Over the years the Company has consistently progressed with remarkable success in both local and international markets. Today, Beximco Pharma is recognized as an emerging global generic pharma company in the region.
With a diverse portfolio of more than 300 products, the Company covers nearly all therapeutic categories, serving the healthcare needs of millions. The Company's state-of-the-art manufacturing facilities and compliance to stringent global regulatory standards have earned it a reputation as a trusted provider of affordable and reliable generic medicines. Beximco Pharma exports its products to over 60 countries, including regulated markets such as the USA, Europe, Canada, and Australia.
Through innovation and a commitment to quality, the Company has achieved consistent growth and gained recognition from various national and international organizations for excellence in pharmaceutical manufacturing and exports. It received the National Export (Gold) trophy nine times.
The Company's long list of accolades includes prestigious international awards such as SCRIP Award 2017 (“Best Pharma Company in an Emerging Market”), Global Generics Biosimilar Awards 2019 (“Company of the Year, Asia Pacific”),
CPhI Pharma Awards 2020 (“Innovation in Response to COVID-19”), and Global Generics Biosimilar Awards 2021 (“Company of the Year, Asia Pacific”).
The Company holds 85.2 stake in Nuvista Pharma Limited (formerly Organon Bangladesh), a leading unlisted pharmaceuticalcompany in Bangladesh specializing in hormone and steroid drugs. In October 2021, it acquired a controlling interest of 54.6 in Sanofi Bangladesh Limited from the Sanofi Group represented through May Baker Limited and Fisons Limited. Subsequent to this acquisition, the company was renamed as Synovia Pharma PLC.
Mission :
We are committed to enhancing human health and well being by providing contemporary and affordable medicines,manufactured in full compliance with global quality standards. We continually strive to improve our core capabilities to address the unmet medical needs of the patients and to deliver outstanding results for our shareholders.
Vision :
We will be one of the most trusted, admired and successful pharmaceutical companies in the region with a focus on strengthening research and development capabilities, creating partnerships and building presence across the globe.
History :
1976 : The Company was incorporated as a Public Limited Company in Bangladesh in 1976.
1980: The Company commenced its manufacturing operation in 1980.
1985 : The Company was listed on Dhaka Stock Exchange in 3 July,1985
1995 : The Company was listed on Chittagong Stock Exchange on its debut in 11 June, 1995 .
2005 : The Company was listed on London Stock Exchange in 21 October 2005.
2016 : The Company changed its year-end from 31 December, 2015 to 30 June, 2016.